Palisade Bio announces first patient dosed in Phase 2b Ascentra-UC study

PALI•2026-10-28

Palisade Bio said the first patient has been dosed in its global Phase 2b Ascentra-UC study of once-daily oral PALI-2108 for ulcerative colitis. Topline results from the 12-week induction period are expected in Q4 2027.

1. Study enrollment begins

Palisade Bio said the first patient has been dosed in the global Phase 2b Ascentra-UC study evaluating once-daily oral PALI-2108 for ulcerative colitis. The company expects topline results from the 12-week induction period in Q4 2027.

Palisade Bio announces first patient dosed in Phase 2b Ascentra-UC study

1. Study enrollment begins

Related News

Frontier swings to surprise profit, sees smaller-than-feared quarterly loss on higher airfares

Mexico's Femsa profit surges 182% in third quarter

Novo Nordisk's semaglutide improves liver health in non-obese MASH patients in trial analysis

Cyabra co-hosts election intelligence luncheon with Carahsoft

C.H. Robinson sees 2026 adjusted diluted EPS of at least $6 at low end of target range